NeuroPace, Inc.
NPCENASDAQHealthcare● Active
$15.65
$-0.10(-0.60%)
Market Cap$533396641
P/E Ratio—
52W High$19.6
52W Low$7.563
NeuroPace, Inc. (NPCE) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NPCE · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.13
Est. -$0.19 · +31.6%
Revenue
$0.02B
Est. $0.02B · +1.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
NPCE reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.19 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.19 | -$0.13 | +31.6% | $0.02B | $0.02B | +1.6% |
| ▲ Q1 FY2026 | Mar 3, 2026 | -$0.14 | -$0.08 | +42.9% | $0.03B | $0.02B | +7.4% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.20 | -$0.11 | +45.0% | $0.03B | $0.03B | +9.3% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.24 | -$0.26 | -8.3% | $0.02B | $0.02B | -3.7% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.26 | -$0.21 | +19.2% | $0.02B | $0.02B | -0.8% |
| ▲ Q1 FY2025 | Mar 4, 2025 | -$0.25 | -$0.18 | +28.0% | $0.02B | $0.02B | -0.4% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.26 | -$0.19 | +26.9% | $0.02B | $0.02B | +0.7% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.13
EPS Est.
-$0.19
EPS Surpr.
+31.6%
Revenue
$0.02B
Q1 FY2026
Mar 3, 2026Beat
EPS Actual
-$0.08
EPS Est.
-$0.14
EPS Surpr.
+42.9%
Revenue
$0.03B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.20
EPS Surpr.
+45.0%
Revenue
$0.03B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.24
EPS Surpr.
-8.3%
Revenue
$0.02B
Q2 FY2025
May 13, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.26
EPS Surpr.
+19.2%
Revenue
$0.02B
Q1 FY2025
Mar 4, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.25
EPS Surpr.
+28.0%
Revenue
$0.02B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.19
EPS Est.
-$0.26
EPS Surpr.
+26.9%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.09 | $-0.08 | $-0.08 | 3 |
| Q3 FY2028 | $-0.12 | $-0.12 | $-0.12 | 2 |
| Q2 FY2028 | $-0.17 | $-0.17 | $-0.16 | 2 |
| Q1 FY2028 | $-0.20 | $-0.20 | $-0.19 | 3 |
| Q4 FY2027 | $-0.02 | $-0.02 | $-0.02 | 2 |
| Q3 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +31.6% | $15.67 | $15.80 | +0.83% |
| ▲ Q1 FY2026 | Mar 3, 2026 | +42.9% | $14.15 | $13.83 | -2.26% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +45.0% | $9.40 | $9.40 | +0.00% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -8.3% | $8.89 | $9.13 | +2.70% |
| ▲ Q2 FY2025 | May 13, 2025 | +19.2% | $13.37 | $12.95 | -3.14% |
| ▲ Q1 FY2025 | Mar 4, 2025 | +28.0% | $11.81 | $11.92 | +0.93% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +26.9% | $7.28 | $7.14 | -1.92% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +10.3% | $6.90 | $7.28 | +5.51% |
Q2 FY2026+0.83%
Report Date
May 12, 2026
EPS Beat/Miss
+31.6%
Price Before
$15.67
Price After
$15.80
Q1 FY2026-2.26%
Report Date
Mar 3, 2026
EPS Beat/Miss
+42.9%
Price Before
$14.15
Price After
$13.83
Q4 FY2025+0.00%
Report Date
Nov 4, 2025
EPS Beat/Miss
+45.0%
Price Before
$9.40
Price After
$9.40
Q3 FY2025+2.70%
Report Date
Aug 12, 2025
EPS Beat/Miss
-8.3%
Price Before
$8.89
Price After
$9.13
Q2 FY2025-3.14%
Report Date
May 13, 2025
EPS Beat/Miss
+19.2%
Price Before
$13.37
Price After
$12.95
Q1 FY2025+0.93%
Report Date
Mar 4, 2025
EPS Beat/Miss
+28.0%
Price Before
$11.81
Price After
$11.92
Q4 FY2024-1.92%
Report Date
Nov 12, 2024
EPS Beat/Miss
+26.9%
Price Before
$7.28
Price After
$7.14
Q3 FY2024+5.51%
Report Date
Aug 13, 2024
EPS Beat/Miss
+10.3%
Price Before
$6.90
Price After
$7.28
Avg Beat Reaction-0.01%
Avg Miss Reaction+2.70%
Beat Rate7 / 8 quarters
Largest Move+5.51% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NPCE ends December
NeuroPace, Inc. (NPCE) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.13 — beating the analyst consensus of $-0.19 by +31.6%. NPCE has beaten EPS estimates for 3 consecutive quarters. The next NPCE earnings date is expected around September 1, 2026.
Each quarter, investors track NPCE earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NPCE revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NPCE's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NPCE earnings · 5 questionsNeuroPace, Inc.'s next earnings report is expected around September 1, 2026. NPCE typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NPCE historically reports after market close (AMC).
NPCE earnings datewhen is NPCE earningsNPCE next earnings datewhen does NPCE report earningsNPCE earnings calendar
▸ Source: FMP · NeuroPace, Inc. SEC filings · US GAAP · NeuroPace, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026